ASCO 2009 Report: Malignant Hematology
MEETING REPORT
Investigators evaluate a new vaccine and salvage therapy for certain lymphomas.
ASCO 2009 Report: Gastrointestinal Cancer
MEETING REPORT
Investigators reported positive and negative results in new trials of GI cancer drugs.
ASCO 2009 Report: Genitourinary Cancer
MEETING REPORT
Trial results of new treatments for prostate, urothelial, and renal cancers
ASCO 2009 Report: Lung Cancer
MEETING REPORT
June 16, 2009
Lin-Chi Chen, MD, PhD
Findings on a range of new therapies, agents, and markers were reported.
ASCO 2009 Report: Breast Cancer
MEETING REPORT
New trials in triple-negative and HER2-negative disease
ASCO 2009 Report
MEETING REPORT
June 16, 2009
The Editors, Journal Watch Oncology and Hematology
Summaries of key findings from the world’s largest oncology conference
Short-Term vs. Long-Term Hormone Therapy for Prostate Cancer
SUMMARY AND COMMENT
Six months (vs. 3 years) of androgen suppression provided inferior survival for patients with locally advanced disease.
Reviewing:
Bolla M et al., N Engl J Med 2009 Jun 11; 360:2516
Albertsen P., N Engl J Med 2009 Jun 11; 360:2572
Survival After Resection of Hepatocellular Carcinoma
SUMMARY AND COMMENT
Tumor size >2 cm, tumor multifocality, and microvascular invasion predicted poor prognoses among patients with early disease.
Reviewing:
Nathan H et al., Ann Surg 2009 May; 249:799
Familial Risk for Chronic Lymphocytic Leukemia
SUMMARY AND COMMENT
First-degree relatives of patients with CLL had elevated risk for lymphoproliferative malignancies, predominantly CLL.
Reviewing:
Goldin LR et al., Haematologica 2009 May; 94:647
Are Anthracyclines Justified for Breast Cancer?
SUMMARY AND COMMENT
Most patients are not likely to benefit from anthracycline-based adjuvant chemotherapy.
Reviewing:
O’Malley FP et al., J Natl Cancer Inst 2009 May 6; 101:644
Slamon DJ and Press MF., J Natl Cancer Inst 2009 May 6; 101:615
